Therapeutic options in mantle cell lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 3, 2008, Pages 398-409

  Gill, Saar ^a   Ritchie, David ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Chemotherapeutic approaches; Clinical results; Lymphoma and Hodgkin disease

Indexed keywords

BORTEZOMIB; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THALIDOMIDE; TOSITUMOMAB I 131; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG FATALITY; EDEMA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; MANTLE CELL LYMPHOMA; MEDLINE; MULTIPLE CYCLE TREATMENT; NEUROMUSCULAR DISEASE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REDUCED INTENSITY CONDITIONING; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MEDLINE; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 39749091156     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701851364     Document Type: Review

References (74)

1. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's Lymphoma. Blood, 89, pp. 3909-3918.
2. (2001) IARC Press, Lyon
3. Campo, E., Raffeld, M. and Jaffe, E. S. (1999) Mantle-cell lymphoma. Semin Hematol, 36, pp. 115-127.
4. Bosch, F., Lopez-Guillermo, A., Campo, E., Ribera, J. M., Conde, E. and Piris, M. A. (1998) Mantle cell lymphoma presenting features, response to therapy, and prognostic factors. Cancer, 82, pp. 567-575.
5. Tiemann, M., Schrader, C., Klapper, W., Dreyling, M. H., Campo, E. and Norton, A. (2005) Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol, 131, pp. 29-38.
6. Romaguera, J. E., Medeiros, L. J., Hagemeister, F. B., Fayad, L. E., Rodriguez, M. A. and Pro, B. (2003) Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer, 97, pp. 586-591.
7. Liu, Z., Dong, H. Y., Gorczycz, W., Tsang, P., Cohen, P. and Stephenson, C. F. (2002) CD5- mantle cell lymphoma. Am J Clin Pathol, 118, pp. 216-224.
8. Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M. and Campo, E. (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3, pp. 185-197.
9. Fu, K., Weisenburger, D. D., Greiner, T. C., Dave, S., Wright, G. and Rosenwald, A. (2005) Cyclin D1-negative mantle cell lymphoma: A clinicopathologic study based on gene expression profiling. Blood, 106, pp. 4315-4321.
10. Armitage, J. O. and Weisenburger, D. D. (1998) New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol, 16, pp. 2780-2795.
11. Andersen, N. S., Jensen, M. K., Brown, P de Nully and Geisler, C. H. (2002) A Danish population-based analysis of 105 mantle cell lymphoma patients: Incidences, clinical features, response, survival and prognostic factors. Eur J Cancer, 38, pp. 401-408.
12. Sweetenham, J. W. (2001) Stem cell transplantation for mantle cell lymphoma: Should it ever be used outside clinical trials?. Bone Marrow Transplant, 28, pp. 813-820.
13. Orchard, J., Garand, R., Davis, Z., Babbage, G., Sahota, S. and Matutes, E. (2003) A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood, 101, pp. 4975-4981.
14. Zucca, E., Roggero, E., Pinotti, G., Pedrinis, E., Cappella, C. and Venco, A. (1995) Patterns of survival in mantle cell lymphoma. Ann Oncol, 6, pp. 257-262.
15. Bertini, M., Rus, C., Freilone, R., Botto, B., Calvi, R. and Novero, D. (1998) Mantle cell lymphoma: A retrospective study on 27 patients. Clinical features and natural history. Haematologica, 83, pp. 312-316.
16. Weisenburger, D. D., Vose, J. M., Greiner, T. C., Lynch, J. C., Chan, W. C. and Bierman, P. J. (2000) Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol, 64, pp. 190-196.
17. Lefrere, F., Delmer, A., Suzan, F., Levy, V., Belanger, C. and Djabarri, M. (2002) Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event free-survival in mantle cell lymphoma: A prospective study. Leukemia, 16, pp. 587-593.
18. Romaguera, J. E., Khouri, I. F., Kantarjian, H. M., Hagemeister, F. B., Rodriguez, M. A. and McLaughlin, P. (2000) Untreated aggressive mantle cell lymphoma: Results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma, 39, pp. 77-85.
19. Cohen, B. J., Moskowitz, C., Straus, D., Noy, A., Hedrick, E. and Zelenetz, A. (2001) Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma, 42, pp. 1015-1022.
20. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A. and Metzner, B. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomised study of the German Low-Grade Lymphoma Study Group. Blood, 104, pp. 3064-3071.
21. Ghielmini, M., Schmitz, S. F., Cogliatti, S., Bertoni, F., Waltzer, U. and Fey, M. F. (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol, 23, pp. 705-711.
22. Foran, J. M., Rohatiner, A. Z., Cunningham, S., Popescu, R. A., Solal-Celigny, P. and Ghielmini, M. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol, 18, pp. 317-324.
23. Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H. P., Repp, R. and Wandt, H. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 108, pp. 4003-4008.
24. Kahl, B. S., Longo, W. L., Eickhoff, J. C., Zehnder, J., Jones, C. and Blank, J. (2006) Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol, 17, pp. 1418-1423.
25. Ladetto, M., Magni, M., Pagliano, G., De Marco, F., Drandi, D. and Ricca, I. (2006) Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant, 12, pp. 1270-1276.
26. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U. and Metzner, B. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol, 23, pp. 1984-1992.
27. Herold, M., Pasold, R., Srock, S., Neser, S., Niederwieser, D. and Neubauer, A. (2004) Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood, 104, p. 584.
28. Schultz, H., Bohlius, J. F., Trelle, S., Skoetz, N., Reiser, M. and Kober, T. (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst, 99, pp. 706-714.
29. Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B. and Pro, B. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol, 23, pp. 7013-7023.
30. Inwards, D. J., Hillman, D. W., Fishkin, P. A., White, W. L., Morton, R. F. and Dakhil, S. R. (2006) Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL). J Clin Oncol, 24, p. 17505.
31. Thomas, D. W., Owen, R. G., Johnson, S. A., Hillmen, P., Seymour, J. F. and Wolf, M. M. (2005) Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma, 46, pp. 549-552.
32. Bauwens, D., Maerevoet, M., Michaux, L., Theate, I., Hagemijer, A. and Stul, M. (2005) Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol, 131, pp. 338-340.
33. Zelenetz, A. D., Noy, A., Pandit-Taskar, N., Scordo, M., Rijo, I. and Zhou, Y. (2006) Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol, 24, p. 7560.
34. 90Y-Ibritumomab Tiuxetan) radioimmunotherapy (RIT) consolidation of FCM induction chemotherapy in mantle cell lymphoma (MCL) patients: Results from the PLRG upon completed enrollment. Blood, 108, p. 2747.
35. 90 Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). J Clin Oncol, 24, p. 7503.
36. 90 Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of the European MCL Network and the PLRG. J Clin Oncol, 24, p. 7533.
37. 90Y) Ibritumomab Tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL). Blood, 106, p. 2452.
38. Freedman, A. S., Neuberg, D., Gribben, J. G., Mauch, P., Soiffer, R. J. and Fisher, D. C. (1998) High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission. J Clin Oncol, 16, pp. 13-18.
39. Dreyling, M., Lenz, G., Hoster, E., Van Hoof, A., Gisselbrecht, C. and Schmits, R. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood, 105, pp. 2677-2684.
40. Khouri, I. F., Saliba, R. M., Okoroji, G. J., Acholonu, S. A. and Champlin, R. E. (2003) Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: The prognostic value of β-2-microglobulin and the tumor score. Cancer, 98, pp. 2630-2635.
41. Andersen, N. S., Pedersen, L., Elonen, E., Johnson, A., Kolstad, A. and Franssila, K. (2003) Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: Outcome related to remission pretransplant. Eur J Haematol, 71, pp. 73-80.
42. Geisler, C. H., Elonen, E., Kolstad, A., Laurell, A., Andersen, N. S. and Pedersen, L. B. (2004) Nordic mantle cell lymphoma (MCL) project: prolonged follow-up of 86 patients treated with BEAM/BEAC + PBSCT confirms that addition of high-dose Ara-C and rituximab to CHOP induction + in-vivo purging with rituximab increases clinical and molecular response rates, PCR-Neg. grafts, failure-free, relapse-free and overall survival. Blood, 104, p. 8.
43. Mangel, J., Leitch, H. A., Connors, J. M., Buckstein, R., Imrie, K. and Spaner, D. (2004) Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: A matched pair analysis. Ann Oncol, 15, pp. 283-290.
44. Dreger, P., Rieger, M., Seyfarth, B., Hensel, M., Kneba, M. and Ho, A. D. (2007) Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: Effects on molecular response and clinical outcome. Haematologica, 92, pp. 42-49.
45. Gianni, A. M., Magni, M., Martelli, M., Nicola, M Di, Carlo-Stella, C. and Pilotti, S. (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood, 102, pp. 749-755.
46. Vandenberghe, E., de Elvira, C Ruiz, Loberiza, Fr, Conde, E. and Lopez-Guillermo, A. (2003) Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol, 120, pp. 793-800.
47. Thieblemont, C., Antal, D., Lacotte-Thierry, L., Delwail, V., Espinouse, D. and Michallet, A. S. (2005) Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer, 104, pp. 1434-1441.
48. Vose, J., Loberiza, F., Bierman, P., Bociek, G. and Armitage, J. (2006) Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/high-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol, 24, p. 7511.
49. Pott, C., Schrader, C., Gesk, S., Harder, L., Tiemann, M. and Raff, T. (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood, 107, pp. 2271-2278.
50. Ritchie, D. S., Seymour, J. F., Grigg, A. P., Roberts, A. W., Hoyt, R. and Thompson, S. (2007) The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol, 86, pp. 101-105.
51. Dreger, P., Martin, S., Kuse, R., Sonnen, R., Glass, B. and Kroger, N. (2000) The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: A joint analysis of two prospective studies with 46 patients. Hematol J, 1, pp. 87-94.
52. Kasamon, Y. L., Jones, R. J., Diehl, L. F., Nayer, H., Borowitz, M. J. and Garrett-Mayer, E. (2005) Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant, 11, pp. 39-46.
53. Lefrere, F., Delmer, A., Levy, V., Delarue, R., Baret, B. and Hermine, O. (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study. Haematologica, 89, pp. 1275-1276.
54. Howard, O. M., Gribben, J. G., Neuberg, Ds, Grossbard, M., Poor, C. and Janicek, M. J. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol, 20, pp. 1288-1294.
55. Gopal, A. K., Ranjendran, J. G., Petersdorf, S. H., Maloney, D. G., Eary, J. F. and Wood, B. L. (2002) High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood, 99, pp. 3158-3162.
56. Gopal, A. K., Rajendran, J. G., Cooley, T. A., Pagel, J. M., Fisher, D. R. and Petersdorf, S. H. (2007) High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol, 25, pp. 1396-1402.
57. Khouri, I. F., Lee, M. S., Saliba, R. M., Jun, G., Fayad, L. and Younes, A. (2003) Nonablative allogeneic stem-cell transplantation for advanced/ recurrent mantle-cell lymphoma. J Clin Oncol, 21, pp. 4407-4412.
58. Maris, M. B., Sandmaier, B. M., Storer, B. E., Chauncey, T., Stuart, M. J. and Maziarz, Rt (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood, 104, pp. 3532-3542.
59. Khouri, I. F., Lee, M. S., Romaguera, J., Mirza, N., Kantarjian, H. and Korblin, M. (1999) Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy. Ann Oncol, 10, p. 1293.
60. Popplewell, L. L., Nademanee, A., Carter, N., Zain, J., Krishnan, A. and Rodriguez, R. (2004) Autologous vs. allogeneic cell transplantation for mantle cell lymphoma (MCL): Outcomes over a 10-year period at city of hope. Blood, 104, p. 894.
61. Ganti, A. K., Bierman, P. J., Lynch, J. C., Bociek, R. G., Vose, J. M. and Armitage, J. O. (2005) Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol, 16, pp. 618-624.
62. Robinson, S. P., Goldstone, A. H., Mackinnon, S., Carella, A., Russell, N. and De Elvira, C. R. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood, 100, pp. 4310-4316.
63. Avivi, I., Canals, C., Taghipour, G., Finke, J., Volin, L. and Beguin, Y. (2006) Matched unrelated donor stem cell transplantation for relapsed or refractory mantle cell lymphoma. A retrospective analysis from the EBMT Lymphoma Working Party. Blood, 108, p. 3123.
64. Belch, A., Kouroukis, C. T., Crump, M., Sehn, L., Gascoyne, R. D. and Klasa, R. (2007) A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol, 18, pp. 116-121.
65. Leonard, J. P., Furman, R. R., Cheung, Y-KK, Feldman, E. J., Cho, H. J. and Vose, J. M. (2005) Phase I/II trial of Bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): Phase I results. Blood, 106, p. 491.
66. Kouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D. and Meyer, R. (2003) Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 21, pp. 1740-1745.
67. Perez-Galan, P., Roue, G., Villamor, N., Montserrat, E., Campo, E. and Colomer, D. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 107, pp. 257-264.
68. Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J. and de Vos, S. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol, 24, pp. 4867-4874.
69. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E. and Hagemeister, F. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 667-675.
70. O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B. and Stubblefield, M. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol, 23, pp. 676-684.
71. Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R. and Kurtin, P. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol, 23, pp. 5347-5356.
72. Ruan, J., Coleman, M., Furman, R. R., Glynn, P., Joyce, M. and Ketas, J. (2006) Targeting angiogenesis in mantle cell lymphoma: Clinical efficacy and correlative studies of a phase II trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in relapsed/refractory disease. Blood, 108, p. 2751.
73. Kaufmann, H., Raderer, M., Wohrer, S., Puspok, A., Bankier, A. and Zielinski, C. (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood, 104, pp. 2269-2271.
74. Wang, M., Fayad, L., Hagemeister, F., Neelapu, S., Bell, N. and Byrne, C. (2007) A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol, 25, p. 8030.